In a late-stage trial, personalized mRNA vaccines for...
In a late-stage trial, personalized mRNA vaccines for melanoma “reduced the risk of death or recurrence by 42 percent compared to standard treatment” .
In a late-stage trial, personalized mRNA vaccines for melanoma “reduced the risk of death or recurrence by 42 percent compared to standard treatment” .